J. Renes et al., ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1, BR J PHARM, 126(3), 1999, pp. 681-688
1 The present study was performed to investigate the ability of the multidr
ug resistance protein (MRP1) to transport different cationic substrates in
comparison with MDR1-P-glycoprotein (MDR1). Transport studies were performe
d with isolated membrane vesicles from in vitro selected multidrug resistan
t cell lines overexpressing MDR1 (A2780AD) or MRP1 (GLC(4)/Adr) and a MRP1-
transfected cell line (S1(MRP)).
2 As substrates we used H-3-labelled derivatives of the hydrophilic monoqua
ternary cation N-(4',4'-azo-n-pentyl)-21-deoxy-ajmalinium (APDA), the basic
drug vincristine and the more hydrophobic basic drug daunorubicin. All thr
ee are known MDR1-substrates,
3 MRP1 did not mediate transport of these substrates per se. In the presenc
e of reduced glutathione (GSH), there was an ATP-dependent uptake of vincri
stine and daunorubicin, but not of APDA, into GLC(4)/Adr and S1(MRP) membra
ne vesicles which could be inhibited by the MRP1-inhibitor MK571.
4 ATP- and GSH-dependent transport of daunorubicin and vincristine into GLC
4/Adr membrane vesicles was inhibited by the MRP1-specific monoclonal antib
ody QCRL-3.
5 MRP1-mediated daunorubicin transport rates were dependent on the concentr
ation of GSH and were maximal at concentrations greater than or equal to 10
mM. The apparent K-M value for GSH was 2.7 mM. Transport of daunorubicin i
n the presence of 10 mM GSH was inhibited by MK571 with an IC50 of 0.4 mu M
.
6 In conclusion, these results demonstrate that MRP1 transports vincristine
and daunorubicin in an ATP- and GSH-dependent manner. APDA is not a substr
ate for MRP1.